Navigation Links
Transposagen Issued Two Key U.S. Patents
Date:11/1/2013

LEXINGTON, Ky., Nov. 1, 2013 /PRNewswire-iReach/ -- Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today the issuing of Patent No. 8,399,643 entitled, "Nucleic Acids Encoding Hyperactive PiggyBac Transposases" on March 19th and Patent No. 8,558,055 entitled, "A Genetically Modified Rat Comprising a Cytokine Gene Disruption and Exhibiting a Greater Susceptibility to a Cytokine-Mediated Autoimmune and/or Inflammatory Disease" on October 15th. The patents have terms extending through 2030.

(Photo: http://photos.prnewswire.com/prnh/20131101/MN08740)

The piggyBacTM DNA transposon is the most efficient and safe technology for delivering DNA stably into the genome of animals and is being used in biomedical, agricultural and human therapeutic applications. Transposagen tested over 2 million variations of the piggyBacTM transposase enzyme and discovered versions of the enzyme that are more than 10 times more active than the version found in nature. The piggyBacTM technology is also a critical component of Footprint-FreeTM Gene Editing, one of the only commercially available methods to edit as little as a single nucleotide in the genome of nearly any organism. "The new 'super piggyBacTM vectors and PB-GoldTM kit, will allow researchers to perform stable transfection for the same cost and on the same timeline as transient transfection." said Jack Crawford, M.Sc., Transposagen's Director of Sales and Marketing.

The more recent patent covers all genetically modified rats that model lymphocyte proliferation, autoimmune disease or inflammatory disease, including all genetically modified rats with dysfunction in macrophages, immunoglobulin, T-cells, B-cells and/or NK-cells. The patent further covers any assay that screens for potentially useful therapeutic compounds using cells derived from the genetically modified rats. "This patent, and other imminent patents that cover genetically modified rat models of cancer and other diseases, cements Transposagen's position as a premier provider of custom genetically modified rodents," said Eric Ostertag, M.D., Ph.D., President & CEO of Transposagen. "We are proud to be the sole provider of valuable research reagents, such as the hyperactive piggyBacTM transposase and rat models of inflammatory disease, to the research community."

Please see piggyBacTM for more information, as well as Disease Model Partnering Strategy for opportunities in rodent model creation.

About Transposagen Biopharmaceuticals:

Transposagen Biopharmaceuticals, Inc. is a worldwide leader in technologies and services for genetic modification. Transposagen specializes in gene editing tools and custom cell line and animal model creation. To learn more, please visit: http://transposagenbio.com/

Media Contact: Jack Crawford, Transposagen Biopharmaceuticals, (315) 351-9115, jcrawford@transposagenbio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Transposagen Biopharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Transposagen Receives Over $4.3M in Grants and Investment
2. Enbrel® (etanercept) Patent Issued
3. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
4. 12th U.S. Patent Issued To Dyadic International
5. Stemedica Issued U.S. Patent For Stem Cell Treatment of Diabetic Retinopathy and Diabetic Optic Neuropathy
6. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
7. Stemedica Issued U.S. Patent For Ectodermal Stem Cells
8. PharmaDirections is Co-inventor on Second Issued Formulation Patent Entitled “Layered Pharmaceutical Formulations”
9. PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
10. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
11. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):